This "Acute Myeloid Leukemia (AML) - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Acute Myeloid Leukemia (AML), historical and forecasted epidemiology as well as the Acute Myeloid Leukemia (AML) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Acute Myeloid Leukemia (AML) market report provides current treatment practices, emerging drugs, Acute Myeloid Leukemia (AML) market share of the individual therapies, current and forecasted Acute Myeloid Leukemia (AML) market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Acute Myeloid Leukemia (AML) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
This segment gives a thorough detail of Acute Myeloid Leukemia (AML) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the publisher, Acute Myeloid Leukemia (AML) market in 7MM is expected to change in the study period 2020-2034.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Reimbursement Scenario in Acute Myeloid Leukemia (AML)
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
The Acute Myeloid Leukemia (AML) market report provides current treatment practices, emerging drugs, Acute Myeloid Leukemia (AML) market share of the individual therapies, current and forecasted Acute Myeloid Leukemia (AML) market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Acute Myeloid Leukemia (AML) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2020-2034
Acute Myeloid Leukemia (AML) Disease Understanding and Treatment Algorithm
The Acute Myeloid Leukemia (AML) market report gives a thorough understanding of the Acute Myeloid Leukemia (AML) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.Diagnosis
This segment of the report covers the detailed diagnostic methods or tests for Acute Myeloid Leukemia (AML).Treatment
It covers the details of conventional and current medical therapies available in the Acute Myeloid Leukemia (AML) market for the treatment of the condition. It also provides Acute Myeloid Leukemia (AML) treatment algorithms and guidelines in the United States, Europe, and Japan.Acute Myeloid Leukemia (AML) Epidemiology
The Acute Myeloid Leukemia (AML) epidemiology division provide insights about historical and current Acute Myeloid Leukemia (AML) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Acute Myeloid Leukemia (AML) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.Country Wise-Acute Myeloid Leukemia (AML) Epidemiology
The epidemiology segment also provides the Acute Myeloid Leukemia (AML) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.Acute Myeloid Leukemia (AML) Drug Chapters
Drug chapter segment of the Acute Myeloid Leukemia (AML) report encloses the detailed analysis of Acute Myeloid Leukemia (AML) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Acute Myeloid Leukemia (AML) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.Marketed Drugs
The report provides the details of the marketed product available for Acute Myeloid Leukemia (AML) treatment.Acute Myeloid Leukemia (AML) Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Acute Myeloid Leukemia (AML) treatment.Acute Myeloid Leukemia (AML) Market Outlook
The Acute Myeloid Leukemia (AML) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Acute Myeloid Leukemia (AML) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.This segment gives a thorough detail of Acute Myeloid Leukemia (AML) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the publisher, Acute Myeloid Leukemia (AML) market in 7MM is expected to change in the study period 2020-2034.
Key Findings
This section includes a glimpse of the Acute Myeloid Leukemia (AML) market in 7MM.The United States Market Outlook
This section provides the total Acute Myeloid Leukemia (AML) market size and market size by therapies in the United States.EU-5 Countries: Market Outlook
The total Acute Myeloid Leukemia (AML) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.Japan Market Outlook
The total Acute Myeloid Leukemia (AML) market size and market size by therapies in Japan is also mentioned.Acute Myeloid Leukemia (AML) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Acute Myeloid Leukemia (AML) market or expected to get launched in the market during the study period 2020-2034. The analysis covers Acute Myeloid Leukemia (AML) market uptake by drugs; patient uptake by therapies; and sales of each drug.This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Acute Myeloid Leukemia (AML) Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Acute Myeloid Leukemia (AML) key players involved in developing targeted therapeutics.Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Acute Myeloid Leukemia (AML) emerging therapies.Reimbursement Scenario in Acute Myeloid Leukemia (AML)
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current market trends, we take KOLs and SME's opinion working in Acute Myeloid Leukemia (AML) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Acute Myeloid Leukemia (AML) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Acute Myeloid Leukemia (AML) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.Scope of the Report
- The report covers the descriptive overview of Acute Myeloid Leukemia (AML), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Acute Myeloid Leukemia (AML) epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Acute Myeloid Leukemia (AML) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Acute Myeloid Leukemia (AML) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Acute Myeloid Leukemia (AML) market
Report Highlights
- In the coming years, Acute Myeloid Leukemia (AML) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- Companies and academics are working to assess challenges and seek opportunities that could influence Acute Myeloid Leukemia (AML) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- The major players are involved in developing therapies for Acute Myeloid Leukemia (AML). Launch of emerging therapies will significantly impact the Acute Myeloid Leukemia (AML) market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Acute Myeloid Leukemia (AML)
- This in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Acute Myeloid Leukemia (AML) Report Insights
- Patient Population
- Therapeutic Approaches
- Acute Myeloid Leukemia (AML) Pipeline Analysis
- Acute Myeloid Leukemia (AML) Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Acute Myeloid Leukemia (AML) Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Acute Myeloid Leukemia (AML) Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Acute Myeloid Leukemia (AML) Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
Key Questions
Market Insights:
- What was the Acute Myeloid Leukemia (AML) market share (%) distribution in 2020 and how it would look like in 2034?
- What would be the Acute Myeloid Leukemia (AML) total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
- What are the key findings pertaining to the market across 7MM and which country will have the largest Acute Myeloid Leukemia (AML) market size during the forecast period (2024-2034)?
- At what CAGR, the Acute Myeloid Leukemia (AML) market is expected to grow in 7MM during the forecast period (2020-2034)?
- What would be the Acute Myeloid Leukemia (AML) market outlook across the 7MM during the forecast period (2020-2034)?
- What would be the Acute Myeloid Leukemia (AML) market growth till 2032, and what will be the resultant market Size in the year 2034?
- How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What is the disease risk, burden and unmet needs of the Acute Myeloid Leukemia (AML)?
- What is the historical Acute Myeloid Leukemia (AML) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Acute Myeloid Leukemia (AML) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Acute Myeloid Leukemia (AML)?
- Out of all 7MM countries, which country would have the highest prevalent population of Acute Myeloid Leukemia (AML) during the forecast period (2020-2034)?
- At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the Acute Myeloid Leukemia (AML) treatment, along with the approved therapy?
- What are the current treatment guidelines for the treatment of Acute Myeloid Leukemia (AML) in the USA, Europe, and Japan?
- What are the Acute Myeloid Leukemia (AML) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Acute Myeloid Leukemia (AML)?
- How many therapies are developed by each company for Acute Myeloid Leukemia (AML) treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Acute Myeloid Leukemia (AML) treatment?
- What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Acute Myeloid Leukemia (AML) therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Acute Myeloid Leukemia (AML) and their status?
- What are the key designations that have been granted for the emerging therapies for Acute Myeloid Leukemia (AML)?
- What are the global historical and forecasted market of Acute Myeloid Leukemia (AML)?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Acute Myeloid Leukemia (AML) market
- To understand the future market competition in the Acute Myeloid Leukemia (AML) market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Acute Myeloid Leukemia (AML) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Acute Myeloid Leukemia (AML) market
- To understand the future market competition in the Acute Myeloid Leukemia (AML) market
Table of Contents
1. Key Insights2. Executive Summary of Acute Myeloid Leukemia (AML)3. Competitive Intelligence Analysis for Acute Myeloid Leukemia (AML)6. Patient Journey9. Unmet Needs10. Key Endpoints of Acute Myeloid Leukemia (AML) Treatment14. Attribute analysis16. Access and Reimbursement Overview of Acute Myeloid Leukemia (AML)17. KOL Views18. Market Drivers19. Market Barriers21. Publisher Capabilities22. Disclaimer
4. Acute Myeloid Leukemia (AML): Market Overview at a Glance
5. Acute Myeloid Leukemia (AML): Disease Background and Overview
7. Acute Myeloid Leukemia (AML) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
11. Marketed Products
12. Emerging Therapies
13. Acute Myeloid Leukemia (AML): Seven Major Market Analysis
15. 7MM: Market Outlook
20. Appendix
23. About the Publisher
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbvie
- Actinium Pharmaceuticals
- AGC Biologics S.p.A.
- Agios Pharmaceuticals
- Aprea Therapeutics
- Aptevo Therapeutics
- Arog Pharmaceuticals
- Astellas Pharma
- Astex Pharmaceuticals, Inc.
- AstraZeneca
- BerGenBio ASA
- Bio-Path Holdings
- Biosight Ltd.
- Bristol Myers Squibb
- Cardiff Oncology
- Celgene
- CellCentric Ltd.
- Chimerix
- Clear Creek Bio Inc.
- Curis, Inc.
- Daiichi Sankyo.
- DCPrime BV
- Delta-Fly Pharma
- Forma Therapeutics
- GEMoaB Monoclonals
- GlycoMimetics Incorporated
- GT Biopharma, Inc.
- Hanmi Pharmaceutical Company Limited
- Immunicum
- ImmunoGen, Inc.
- Immunomedics, Inc.
- Incyte Corporation
- Jazz Pharmaceuticals
- MacroGenics
- NexImmune Inc.
- Novartis
- Novartis Oncology
- Novartis Pharmaceuticals
- Pfizer
- Precigen, Inc.
- Rafael Pharmaceuticals Inc.
- Sellas Life Sciences Group
- Sumitomo Dainippon Pharma Co., Ltd.
- Syndax Pharmaceuticals
- Synimmune GmbH
- Takeda
- Xencor, Inc.
